Arthritis Research & Therapy

Table 2 Association of the four single-nucleotide polymorphisms with changes in Disease Activity Score in 28 joints at 6 and 12 months in Spanish rheumatoid arthritis patients ^a

From: Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis

			6 months						12 months
			Collection 1 (N= 419)			Collection 2 (N= 193)			Collection 1 (N= 314)			Collection 2 (N= 134)
SNP	*Locus*	1/2	MAF	P-value^b	β^b	MAF	P-value^b	β^b	MAF	P-value^b	β^b	MAF	P-value^b	β^b
rs12081765	Intergenic	A/G	0.415	0.570	0.055	0.458	0.995	0.001	0.411	0.716	0.043	0.408	0.677	0.062
rs1532269	PDZ2D	C/G	0.375	0.831	0.020	0.418	0.830	0.022	0.400	0.647	0.051	0.420	0.022	0.335
rs17301249	EYA4	C/G	0.121	0.181	−0.190	0.132	0.458	0.120	0.131	0.416	−0.137	0.154	0.529	0.135
rs7305646	Intergenic	T/C	0.474	0.244	−0.117	0.487	0.661	−0.049	0.486	0.182	−0.161	0.473	0.554	−0.093

^a1, Minor allele, 2, Major allele; MAF, Minor allele frequency; SNP, Single-nucleotide polymorphism. ^bAdjusted for gender, anti–tumor necrosis factor treatment and Disease Activity Score in 28 joints at baseline.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com